No Data
Boji Medical Technology (300404.SZ): Currently, there are no projects related to monkeypox.
According to an investor interaction platform on January 14, Gelonghui reported that Boji Medical Technology (300404.SZ) is a professional CRO service provider, mainly offering pharmaceutical research and development outsourcing services, and currently has no projects related to monkeypox.
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Boji Medical Technology (300404.SZ): Received the notice of approval for clinical drug trials.
On December 24, Gelonghui reported that Boji Medical Technology (300404.SZ) announced that the "TBA Tablets" developed in collaboration with Guangdong Gumai Di Health Technology Co., Ltd. has received the "Notice of Approval for Clinical Drug Trials" issued by the National Medical Products Administration. TBA is a new, structurally defined compound with pharmacological effects and clinical value. It is a first-class Innovative Drug that has not been marketed domestically or internationally, with a proposed indication for drug-resistant pulmonary tuberculosis. Tuberculosis is a chronic and deadly infectious disease that is transmitted globally, primarily caused by Mycobacterium tuberculosis. TBA acts on the electron transport of mycobacteria.
Express News | Boji Medical Technology: TBA tablets have received approval for clinical trials.
Express News | boji medical technology: the company has been recognized as a national-level specialized, special and new "little giant" enterprise
Boji Medical Technology (300404.SZ) shareholders Zhao Lingli and Fermi No. 13 completed shareholding, totaling a 1.5% reduction in shares.
boji medical technology (300404.SZ) announced that the company has received the unanimous consent of the controlling shareholder and actual controller, Mr. Wang Tingchun...
